Oncolytics to Present REO 033 Colorectal Cancer Trial Abstract at ESMO
Oncolytics says its study launched earlier this year is expected to assess a prior efficacy signal in second-line KRAS-mutant MSS colorectal cancer: 17 months of progression-free survival versus six months for historical standard of care.